Memantina Biofarmoz

Memantine Hydrochloride, the active ingredient in Memantina Biofarmoz, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients.

GNH USA supplies Memantina Biofarmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Biofarmoz is a NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders.

Alzheimer’s disease (moderate to severe): improves cognition, memory and daily functional abilities. Alzheimer’s disease (mild to moderate) as add‑on therapy: may provide additional benefit when combined with cholinesterase inhibitors. Behavioral disturbances in Alzheimer’s disease: may reduce agitation, aggression and psychotic symptoms.

Memantina Biofarmoz may cause a range of adverse reactions. Most are mild and reversible, but serious events can occur.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion or mild hallucinations - Fatigue or somnolence - Hypertension

Serious or Rare Side Effects: - Seizures - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Cardiac arrhythmias - Neuroleptic malignant‑like syndrome - Acute psychosis

Before initiating therapy, consider the following safety measures.

Renal impairment: adjust dose or monitor plasma levels in patients with reduced kidney function. History of seizures: monitor closely for increased seizure activity. Cardiovascular disease: assess blood pressure and cardiac status regularly. Concurrent NMDA antagonists: avoid co‑administration to prevent additive neurotoxicity. Pregnancy and lactation: safety not established; use only if clearly needed. Store at ambient temperature: keep in the original container, protect from moisture and light.

Memantina Biofarmoz can interact with several medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can lead to severe CNS effects. - Other NMDA receptor antagonists: avoid concurrent use.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): monitor for enhanced cognitive effects and side‑effects. - Diuretics (e.g., furosemide): may raise memantine plasma concentrations. - CNS depressants (e.g., benzodiazepines): may increase dizziness and somnolence.